Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887388 · ClinicalTrials.gov registry record · NA
Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers
A NA study of Pathologic Processes, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT05887388: Completed NA study of Pathologic Processes, sponsored by University of North Carolina, Chapel Hill.
NCT05887388 is a NA study of Pathologic Processes that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 38 participants, below the 892-participant average among 13 other Pathologic Processes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887388, a NA study of Pathologic Processes, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This primary purpose of this study will be to (1) examine the feasibility and acceptability of transitional care focusing on care needs of skilled nursing facility (SNF) patients with dementia and their caregivers (primary aim). The secondary purpose will be to describe the effect of the intervention on SNF patient outcomes (preparedness for discharge, quality of life, function and acute care use) and caregiver outcomes (preparedness for the caregiving role, caregiver burden and caregiver distress).
Primary Outcome
Feasibility will measured using an instrument to audit skilled nursing facility medical records of the patient and the intervention log of services for the Patient and Caregiver dyad. It includes eight dichotomous (yes-no) items that indicate feasibility of the Connect-Home Plus intervention. The feasibility items include: (1) completing the Transition Plan of Care; (2) convening the care plan meeting with caregiver attending; (3) reviewing advance directives in the SNF; (4) scheduling follow-up
Conditions Studied
Interventions
- BEHAVIORAL Connect-Home Plus
Study Locations (1)
North Carolina
- UNC-Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2022-03-18 |
| Phase | NA |
What the finished NCT05887388 record still lists
NCT05887388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 892-participant average among 13 other Pathologic Processes trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pathologic Processes appearing as the primary indexed condition, and to 1 intervention - of which Connect-Home Plus is the first listed.
NCT05887388 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05887388 about?
NCT05887388 is a clinical study titled "Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and Their Caregivers". This primary purpose of this study will be to (1) examine the feasibility and acceptability of transitional care focusing on care needs of skilled nursing facility (SNF) patients with dementia and their caregivers (primary aim). The secondary purpose will be to describe the effect of the interventio...
What is the current status of trial NCT05887388?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2021-09-10. Estimated completion is 2022-03-18.
What conditions does trial NCT05887388 study?
This clinical trial studies the following conditions: Pathologic Processes.
What interventions are being tested in trial NCT05887388?
The interventions under investigation include: Connect-Home Plus (BEHAVIORAL).
Who is sponsoring clinical trial NCT05887388?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887388 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pathologic Processes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05887388's enrollment target sits among peer trials
38 12th of 13 higher than 2 of 13 other Pathologic Processes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pathologic Processes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
RECRUITING · NA
-
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
RECRUITING · NA
-
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
ACTIVE NOT RECRUITING · NA
-
Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention
ACTIVE NOT RECRUITING · NA
-
pRESET for Occlusive Stroke Treatment
COMPLETED · NA
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI